BRIEF published on 04/02/2025 at 18:10, 1 year 7 months ago EXACOMPTA CLAIREFONTAINE publie ses résultats financiers 2024 Baisse Des Revenus Résultats Financiers 2024 Conditions Du Marché Perspectives 2025 Performance Du Segment
REGULATED PRESS RELEASE published on 04/02/2025 at 18:05, 1 year 7 months ago Financial statements - 31 december 2024 EXACOMPTA CLAIREFONTAINE Board of Directors approved 2024 financial statements. Revenue: €831,274,000. Outlook cautious due to weak Q1 2025 demand Financial Statements Revenue Outlook 2024 Exacompta Clairefontaine
BRIEF published on 03/27/2025 at 18:05, 1 year 7 months ago EXACOMPTA CLAIREFONTAINE : Résultats annuels 2024 et perspectives 2025 Résultats 2024 Marché De La Papeterie Perspectives 2025 Production De Papier Dividende Action
BRIEF published on 03/27/2025 at 18:05, 1 year 7 months ago EXACOMPTA CLAIREFONTAINE: 2024 annual results and 2025 outlook Stationery Market 2024 Results Outlook 2025 Dividend Share Paper Production
REGULATED PRESS RELEASE published on 03/27/2025 at 18:00, 1 year 7 months ago Arrêté des comptes au 31 décembre 2024 et perspectives 2025 Réunion du conseil d'administration d'EXACOMPTA CLAIREFONTAINE le 27 mars 2025 à Paris pour examen des comptes 2024 et perspectives 2025 Conseil D'administration Résultats 2024 Exacompta Clairefontaine Réunion Perspectives 2025
BRIEF published on 03/03/2025 at 18:05, 1 year 8 months ago Voting Rights and Shares 2024: Exacompta Clairefontaine Report Share Capital Voting Rights Actions Financial Market Exacompta Clairefontaine
BRIEF published on 03/03/2025 at 18:05, 1 year 8 months ago Droits de Vote et Actions 2024 : Bilan d'Exacompta Clairefontaine Marché Financier Droits De Vote Capital Social Actions Exacompta Clairefontaine
REGULATED PRESS RELEASE published on 03/03/2025 at 18:00, 1 year 8 months ago Droits de vote et actions 2024 EXACOMPTA CLAIREFONTAINE déclare le nombre total de droits de vote et d’actions composant son capital pour l'année 2024 Capital Droits De Vote Actions 2024 Exacompta Clairefontaine
BRIEF published on 09/30/2024 at 18:05, 2 years 1 month ago EXACOMPTA CLAIREFONTAINE validates its eligibility for PEA-PME PEA-PME Investment Euronext Growth Exacompta Clairefontaine Eligibility
BRIEF published on 09/30/2024 at 18:05, 2 years 1 month ago EXACOMPTA CLAIREFONTAINE valide son éligibilité au PEA-PME PEA-PME Investissement Euronext Growth Éligibilité Exacompta Clairefontaine
Published on 11/06/2026 at 22:15, 2 days 11 hours ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 2 days 20 hours ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 days 21 hours ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 days 21 hours ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/09/2026 at 09:00, 32 minutes ago Cantourage further develops Telecan and strengthens digital access to medical care
Published on 11/09/2026 at 09:00, 33 minutes ago Municipality Finance issues a GBP 50 million tap under its MTN programme
Published on 11/09/2026 at 09:00, 33 minutes ago Municipality Finance issues EUR 47.5 million zero coupon notes under its MTN programme
Published on 11/09/2026 at 09:00, 33 minutes ago Original-Research: EBRO MOTORS GROUP EV SA (von NuWays AG): BUY
Published on 11/09/2026 at 07:00, 2 hours 33 minutes ago bioMérieux receives U.S. FDA 510(k) clearance for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens including norovirus
Published on 11/09/2026 at 07:00, 2 hours 33 minutes ago BIOPHYTIS ANNOUNCES THE OPERATIONAL LAUNCH OF ITS JOINT VENTURE IN CHINA
Published on 11/09/2026 at 07:00, 2 hours 33 minutes ago Biophytis annonce le démarrage opérationnel de sa co-entreprise en Chine
Published on 11/09/2026 at 07:00, 2 hours 33 minutes ago bioMérieux obtient l’autorisation 510(k) de la FDA américaine pour les dernières versions des tests BIOFIRE® FILMARRAY® Gastrointestinal Panels afin d’optimiser la détection des pathogènes gastrointestinaux, dont le norovirus
Published on 11/06/2026 at 19:06, 2 days 14 hours ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
